PATENT CLAIM ANALYSIS

Application Number: 16230737
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "235800"]

Abstract:
The present invention relates to a dosage regimen for a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a dosage regimen for the treatment of patients suffering from a proliferative disease, such as, for example, cancer, with a phosphatidylinositol 3-kinase (PI3K) inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof.

Claim (Index 16):
A method of treating cancer selected from head and neck cancer in a human patient in need of such treatment, comprising administering to said human patient a compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof in a therapeutically effective amount of 60 to 120 mg daily.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14400444', '14137978', '12161537', '13471111', '14686418']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7432633035194415
- 35 USC 102 Novelty (BERT): 0.5029436823706847
- Combined Prediction Score: 0.7192313414045658
- Mean Citation Score: 198.212702
- Max Citation Score: 256.01938
- Similarity Product: 182.3957343720889

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test